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ABSTRACT  
Background and Aims: Although the growth suppressor Hippo pathway has been 
implicated in hepatocellular carcinoma (HCC) pathogenesis, it is unknown at which stage 
of hepatocarcinogenesis its dysregulation occurs. We investigated in early rat and human 
preneoplastic lesions whether overexpression of the transcriptional co-activator Yes-
associated protein (YAP) is an early event.  
Methods: The experimental model used is the Resistant-Hepatocyte (R-H) rat model. 
Gene expression was determined by qRT-PCR or immunohistochemistry. Forward genetic 
experiments were performed in human HCC cells and in murine oval cells. 
Results All foci of preneoplastic hepatocytes generated in rats 4 weeks after 
diethylnitrosamine (DENA) treatment, displayed YAP accumulation. This was associated 
with down-regulation of the β-TRCP ligase, known to mediate YAP degradation, and of 
microRNA-375, targeting YAP. YAP accumulation was paralleled by up-regulation of its 
target genes. Increased YAP expression was also observed in early dysplastic nodules  
and adenomas in humans. Animal treatment with verteporfin (VP), which disrupts the 
formation of the YAP–TEAD complex, significantly reduced preneoplastic foci and oval cell 
proliferation. In vitro experiments confirmed that VP-mediated YAP inhibition impaired cell 
growth in HCC and oval cells; notably, oval cell transduction with wild type or active YAP 
conferred tumorigenic properties in vitro and in vivo.  
Conclusions: These results suggest that i) YAP overexpression is an early event in rat 
and human liver tumorigenesis; ii) it is critical for the clonal expansion of carcinogen-
initiated hepatocytes and oval cells, and, iii) VP-induced disruption of YAP-TEAD 
interaction may provide an important approach for the treatment of YAP-overexpressing 
cancers.  
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INTRODUCTION  
Hepatocellular carcinoma is the fifth most common neoplasm and the third leading cause 
of cancer-related mortality worldwide [1]. HCC carries a dismal prognosis, potentially 
curative surgery being possible only in the subset of patients diagnosed at the early stages 
of the disease. Although some responses are seen with conventional and targeted 
chemotherapies, their impact on overall survival is modest. For this reason, a more 
complete understanding of the molecular mechanisms involved in HCC development could 
have a significant influence on improving therapeutic strategies for this pathology [2].  
Recently, landmark studies have implicated the Hippo signaling pathway in the 
pathogenesis of HCC [3-5]. First identified in Drosophila, this pathway has emerged as an 
evolutionarily conserved mechanism that restricts organ size in different species. In 
mammals, this organ size regulator comprises several tumor suppressors (Mst1/2, 
Sav1/WW45, Lats1/2 and Mob1), acting in a kinase cascade that culminates in the 
phosphorylation and inactivation of the transcriptional co-activator YAP. On the contrary, 
uninhibited YAP localizes in the nucleus where it serves as a co-activator for the TEA-
domain family member (TEAD) group of DNA-binding transcription factors. The YAP/TEAD   
complex promotes proliferative and survival programs by inducing the expression of target 
genes [4-6]. Notably, both the transgenic overexpression of YAP in mice [3,7] and the 
liver-specific knockout of Mst1/2 or Sav1 [8-11] expanded the liver size and ultimately 
induced HCC, revealing a significant role for the Hippo pathway in regulating organ size 
and tumorigenesis in mammals. In humans, amplification of the chromosomal region 
containing the YAP gene (11q22) has been reported in several tumor types [12]. 
Consistent with these findings, the comprehensive survey of the most common solid 
cancer types revealed elevated YAP protein levels and nuclear localization in multiple 
human cancers, including HCC, cholangiocarcinoma (CC) and hepatoblastoma (HB) 
[5,13]. Furthermore, clinical studies showed that YAP was an independent prognostic 
marker for overall survival and disease-free survival for HCC patients and that it was 
associated with tumor differentiation [14]. 
Interestingly, the mammalian Hippo pathway is required to repress the activation of 
facultative adult liver stem cells, known as oval cells [15]. In normal adult liver, oval cells 
progenitors are localized in biliary ductules (canals of Hering) and are bipotential. Although 
hepatic oval cells are not commonly observed in physiological conditions, they can be 
isolated from liver following certain types of injury, such as treatments in which 
hepatocytes are unable to proliferate in response to toxic damage (e.g. treatment with 3,5-
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diethoxycarbonyl-1,4-dihydrocollidine or choline-deficient diets and ethionine (16-18). Oval 
cell homeostasis is regulated by the Hippo pathway, as Mst1/2 or Sav1 ablation in mouse 
liver resulted in abundant oval cell accumulation [9,11].  
A well-known protocol that induces a rapid expansion of the oval cell population is the 
Resistant-Hepatocyte (R-H) rat model [19]. In this model, the need to regain parenchymal 
cell mass after 2/3 partial hepatectomy (PH) leads to the rapid expansion of preneoplastic 
hepatocytes and oval cells, since proliferation of normal hepatocytes is completely 
inhibited by 2-acetylaminofluorene (2-AAF). Therefore, the advantage of this model is that 
it allows to investigate not only the evolution of the early preneoplastic lesions to fully 
developed HCCs, but also the expansion of oval cells.   
Since the Hippo signaling pathway holds great promise in liver cancer therapy, but no 
information are available on the stage (early or late) at which it may play a critical role, the 
aim of the present study was to investigate the role of the Hippo-YAP pathway in the early 
stages of HCC development and in oval cell proliferation. Moreover, we also wanted to 
investigate if pharmacological YAP inhibition could impact on the hepatocarcinogenic 
process. 
 
MATERIALS AND METHODS 
 
Animals and Treatment  
Guidelines for Care and Use of Laboratory Animals were followed during the investigation. 
All animal procedures were approved by the Ethical Commission of the University of 
Cagliari and the Italian Ministry of Health. Male Fischer F-344 rats (100-125g) were 
purchased from Charles River (Milan, Italy).  
R-H Protocol: Rats injected intraperitoneally with diethylnitrosamine (DENA, 150 mg/kg 
body weight, Sigma-Aldrich, Milan, Italy) were subjected to the R-H model (for details, see 
Supporting Material). Animals were sacrificed 7 days after surgery (4 weeks after DENA) 
or 10 weeks and 14 months thereafter. The number of preneoplastic foci positive for the 
placental form of glutathione S-transferase (GSTP) was determined as previously 
described [20]. To investigate the effect of verterporfin (VP) (CAS number: 129497-78-5; 
USP Reference Standards) on early preneoplastic foci and oval cells, F-344 rats were 
exposed to the R-H protocol. VP was administered intraperitoneally (100 mg/kg) 1 hour 
prior to- and 3 and 5 days after PH. Animals were sacrificed 7 days after surgery. 
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CMD protocol: Four week-old male F-344 rats were initiated with DENA (150 mg/kg) and 
2 weeks later fed a choline-methionine deficient (CMD) [21] diet for 4 months. 
Preneoplastic lesions were detected by GSTP staining. 
Effect of VP on TCPOBOP-induced mouse hepatomegaly: The effect of VP on 
TCPOBOP-induced hepatomegaly was investigated in CD-1 female mice (See Supp. 
Material).  
Immunohistochemistry 
Immediately after sacrifice, liver sections were fixed in 10% formalin or snap-frozen in 
liquid nitrogen. For details see Supp. Material.  
Laser-capture Micro-dissection (LMD) 
We microdissected 400 foci (1 week after PH), 20 nodules (10 weeks after initiation with 
DENA), and 9 HCCs (14 months), and random areas of surrounding GSTP-negative 
hepatocytes. Oval cells were also microdissected 1 week after PH. Microdissection was 
performed according to [22] (for details see Supp. Material).  
qRT-PCR analysis 
RNA was retro-transcribed using the High Capacity Kit (Life Technology). Analysis of YAP, 
β-TRCP, Birc-5, Ccnd1, c-myc, Gpc3 and Spp1 was performed using specific TaqMan 
probes (Life Technology) and GAPDH as endogenous control. 
Cell lines 
Human HCC cell lines, MLP29 mouse oval cells and RH rat cell lines were cultured as 
described in Supp. Material. Transduction of cells was performed as described in [23]. 
Clinical features and histopathological diagnosis 
For clinical features and histopathological diagnosis of 28 liver samples, see Table 1, 
Supp. Table 1 and Supp. Material.  
Statistical Analysis. Comparison between treated and control group was performed by 
Anova and student’s t-test Instant Software. 
 
RESULTS 
 
YAP accumulates in early preneoplastic lesions and oval cells.  
To investigate whether derangement of the Hippo pathway is an early event in 
hepatocarcinogenesis, we used the Resistant-Hepatocyte (R-H) rat model [19]. This model 
is characterized by a synchronous expansion of carcinogen-initiated cells that can be 
easily identified by preneoplastic markers as early as 7 days after PH. Unlike normal 
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hepatocytes, preneoplastic hepatocytes and oval cells, are capable to divide after 2/3 PH, 
in the presence of the cytostatic environment generated by 2-AAF. This experimental 
model thus offers the advantage of studying the carcinogenic process from its very initial 
steps. As seen in Fig. 1A, immunohistochemistry of more than 300 foci, performed on 
serial liver sections 7 days after PH, showed that all the hepatocyte foci positive for the 
preneoplastic marker GSTP, were also homogeneously positive for YAP and its 
phosphorylated form (pYAP). Thus, YAP represents an extremely sensitive marker of 
preneoplastic stages. As already described in the original work (19), a massive expansion 
of oval cells (identified by their morphological feature and by positivity to GGT, KRT-19 
and GSTP, data not shown) was observed. Notably, while YAP positivity was also 
detected in the vast majority of proliferating oval cells, an almost negligible YAP staining 
could be observed in the surrounding hepatocytes (Fig. 1B). YAP staining was also 
observed at later stages, namely 10 weeks (a time when nodules shared 
histomorphological characteristic with human dysplastic nodules) [24], (Fig. 1C) and 14 
months (fully malignant HCCs, and lung metastases, Fig. 1D). Cholangiocarcinomas 
(CCs) detected 14 months after initiation were also strongly positive for YAP (Supp. Fig. 
1). Unlike very early stages, characterized by a homogenous positivity of all preneoplastic 
cells, YAP staining in dysplastic nodules was not uniformly distributed (Fig. 1C). Notably, 
while YAP staining was mainly limited to the cytoplasm of early preneoplastic and 
dysplastic hepatocytes and of oval cells, a clear nuclear staining was evident only in HCCs 
and CCs (Fig. 1D; Supp. Fig. 1).  
YAP cytoplasmic accumulation is associated to down-regulation of β-TRCP. 
To investigate whether YAP protein overexpression was paralleled by augmented mRNA 
levels, we performed qRT-PCR analyses on microdissected early preneoplastic foci and 
HCCs. As shown in Fig. 1E, no increase of YAP mRNA was detected at any of the time 
points examined. Since the increase of the YAP protein was not mediated by 
transcriptional mechanisms, we wondered if the observed increased level of YAP protein 
could be due to impaired protein degradation. Indeed, preneoplastic foci exhibited a 
marked down-regulation of the β-TRCP E3 ligase, known to mediate YAP degradation [25] 
(Fig. 1F). 
 
miR-375 is downregulated in YAP-overexpressing preneoplastic nodules and HCCs.  
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MiR-375, that is down-regulated in human HCCs [26] and in a YAP overexpressing mouse 
model of liver chemical carcinogenesis [27], regulates YAP expression and impairs HCC 
cells tumorigenic properties [26]. To investigate whether miR-375 down-regulation 
parallels YAP increase in early lesions, we performed a RT-PCR in 10 dysplastic nodules. 
MiR-375 was significantly down-regulated in preneoplastic lesions (P< 0.01) (Fig. 1G), 
suggesting that it can contribute to YAP increase at early stages of liver tumorigenesis. 
Notably, down-regulation of miR-375 was maintained in HCCs as well, suggesting its 
relevant role in HCC development (Fig. 1H). 
YAP target genes are up-regulated in very early preneoplastic foci and in oval cells.  
As shown by IHC (Fig. 1), YAP was overexpressed in the cytoplasm of highly proliferating 
cells (preneoplastic hepatocytes and oval cells) and barely detectable in the nuclei. Since 
it is possible that a relatively small increase of nuclear YAP cannot be detectable by IHC 
(similar to what observed for β-catenin in mouse liver adenomas where, in spite of 
activating mutations of the gene, cytoplasmic, but not nuclear staining was reported [28], 
we directly investigated YAP transcriptional activation by measuring the expression of its 
target genes. Microarray analysis of YAP target genes performed in microdissected foci 
generated 7 days after PH showed that most of the previously identified YAP target genes 
[29] were up-regulated in early lesions compared to the surrounding non-preneoplastic 
liver (Supp. Fig. 2A). qRT-PCR performed to validate some of these genes and to 
investigate the expression of other YAP target genes not present in the array is shown in 
Supp. Fig. 2B. A high expression of YAP-target genes was observed in microdissected 
oval cells (Supp. Fig. 2C).  
 
YAP accumulation at early stages of hepatocarcinogenesis is not restricted to the 
R-H model. 
To investigate whether YAP accumulation is an event unique to the R-H model of 
hepatocarcinogenesis, we studied a different rat model consisting of a choline-devoid 
methionine-deficient diet [21], and characterized by extensive fatty liver. IHC analysis 
showed a strong YAP accumulation in preneoplastic lesions (Supp. Fig. 3), suggesting 
that an early increase of YAP is a common event in multistage hepatocarcinogenesis. 
 
The TEAD-YAP binding disruptor Verterporfin inhibits the growth of preneoplastic 
foci and oval cell proliferation.  
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Formation of complexes between YAP and the TEAD/TEF transcription factors is 
mandatory for unleashing YAP oncogenic activity [30]. Treatment with the porphyrin 
verteporfin (VP) disrupts the formation of the YAP/TEAD complex, thus impairing the 
transcription of YAP target genes [29]. To investigate whether YAP co-transcriptional 
activation is required for the clonal expansion of DENA-initiated hepatocytes, we 
administered VP to rats exposed to the R-H protocol. VP caused a significant reduction of 
the number of GSTP-positive preneoplastic foci (111.8 vs. 79.6/cm2, P<0.05) and of their 
average size (0.035 vs. 0.023 mm2; P<0.01) (Fig. 2A,B).  
Resection of 2/3 of the liver in the presence of the cytostatic environment generated by 2-
AAF causes a massive expansion of oval cells, expressing markers specific for biliary 
epithelial cells (for example KRT-19). While oval cells observed in DENA-AAF-PH-treated 
animals strongly expressed KTR-19, KRT-19 immunoreactivity in VP treated rats was 
restricted to bile ductular epithelial cells, thus demonstrating the complete inhibitory effect 
of VP on infiltration of liver parenchyma by oval cells (Fig. 2C). This suggests that YAP-
TEAD interaction is an absolute requirement for the proliferation of this progenitor cell 
compartment.  
 
VP-mediated YAP inhibition impairs viability of HCCs and oval cells.  
To further investigate the effect of VP, in vitro experiments were performed on Huh7 HCC 
cells transduced with YAP (Supp. Fig. 4A) or the empty vector. As shown in Fig. 2D, VP 
impaired the growth of control Huh7 cells, while a much weaker effect was observed on 
cells transduced with YAP, suggesting that high levels of YAP protect cells from VP. VP 
also impaired both the viability and the colony forming ability of rat tumorigenic cells 
derived from HCCs generated by the R-H model (Supp. Fig. 4B-C). 
The effect of VP was evaluated in oval cells as well. To mimic the physiological stimuli 
present in a damaged liver, we treated mouse oval cells (MLP29), with Hepatocyte Growth 
Factor (HGF), known to stimulate their growth. As shown in Fig. 2E, VP inhibited HGF-
induced proliferation.  
 
YAP overexpression confers tumorigenic and metastatic properties to oval cells.  
The Hippo signaling pathway plays a pivotal role in regulating oval cells, putative liver 
cancer progenitor cells [15]. As oval cells in the livers of R-H rats are positive for YAP (Fig 
1B), we investigated the effect of YAP overexpression in MLP29 cells. Cells were 
transduced with the empty vector (MLP29 pRRL2), wild type YAP (MLP29 YAP wt) or a 
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YAP active form mutated in Serines 127 and 381 (MLP YAP SS); this form is preferentially 
translocated into the nucleus and is more stable [31] (Supp. Fig. 4D). As shown in Fig. 
3A, YAP WT overexpressing MLP29 cells acquired the ability to grow in anchorage-
independent conditions; the effect was significantly stronger in cells overexpressing active 
YAP (YAP SS). 
To test their tumorigenic ability, we subcutaneously inoculated MLP29 cells in nude mice. 
Tumors generated by MLP29 YAP WT and MLP YAP SS cells were bigger than those of 
MLP29 control cells (Fig. 3B). Moreover, mice inoculated with MLP29 YAP WT or MLP29 
YAP SS presented several and large lung metastases (Fig. 3C); the number and the size 
of metastases was significantly higher in mice inoculated with MLP29 YAP SS cells (Fig 
3D). All together these data suggest that YAP overexpression promotes the tumorigenic 
and metastatic properties of oval cells. 
 
VP inhibits nuclear receptor-mediated hepatomegaly. 
A recent study on transgenic mice reported that while YAP-TEAD interaction is 
dispensable for the achievement of normal liver size, it is required for organ overgrowth 
[29]. To examine whether this mechanism is operating also in genetically unmodified 
animals, we induced liver hyperplasia by the powerful liver mitogen TCPOBOP, a ligand of 
the constitutive androstane receptor (CAR). In agreement with our previous reports [27], a 
single treatment with TCPOBOP induced hepatomegaly within 3 days, which was 
associated with a striking increase of hepatocyte proliferation (Supp. Fig. 5A-C). Nuclear 
translocation of YAP was often observed in hepatocytes from the hyperplastic liver. (Supp. 
Fig. 5D). Treatment with VP reduced TCPOBOP-induced hepatomegaly, strongly impaired 
hepatocyte proliferation (Supp. Fig. 5A-C), and decreased the number of hepatocyte 
nuclei positively stained for YAP (Supp. Fig. 5D). Similarly, the expression of the YAP 
target Birc-5 was poorly induced after TCPOBOP+VP treatment versus TCPOBOP alone, 
indicating decreased activation of YAP (Supp. Fig. 6).  
 
YAP accumulation in human hepatic tumorigenesis 
To investigate at which stage YAP accumulation takes place in human hepatic 
tumorigenesis, we examined its expression in early dysplastic nodules (Table 1). YAP 
immunoreactivity was negligible in the cirrhotic parenchyma, but visible in early dysplastic 
lesions, as isolated cells or sporadic clusters (Fig. 4A-C). YAP immunoreactivity increased 
from early HCC to advanced HCC, the highest expression being in poorly differentiated 
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HCC (Supp. Fig. 7A-C). Cholangiocarcinomas (Supp. Table 1, Supp. Fig. 7D-F) showed 
cytoplasmic and nuclear immunoreactivity, regardless tumor differentiation. YAP levels 
were not associated with clinical parameters such as viral infections or alfa-fetoprotein, but 
rather with HCC grade (Supp. Fig. 7A-C). However, the small number of investigated 
cases did not allow drawing definitive conclusions.  
We also examined neoplastic progression in the so-called healthy liver, whereby 
hepatocellular adenomas are associated or not with HCC development (Table 1, Fig. 4). 
YAP immunoreactivity was seen in different varieties of adenomas such as the β-catenin-
activated (Fig. 4D-F), steatotic (or HNF-α mutated) (Fig. 4G-I), and 
telangiectatic/inflammatory (Fig. 4L-N) subtypes, with abrupt disappearance in the 
adjacent non-neoplastic liver. YAP expression varied from 10 to 80% of neoplastic cells, 
and the pattern of staining was mostly cytoplasmic, diffuse or granular (Fig. 4C,F,I,N), with 
occasional nuclear accumulation (Fig. 4F). In HCC arising in the context of an adenoma 
(Table 1, case 16 & 17), the number of YAP immunoreactive cells was not different from 
that of the adjacent adenoma, but they showed increased YAP expression as compared to 
HCCs taking place in the cirrhosis-dysplasia-HCC sequence (Supp. Table 1, cases 1 to 
7). YAP immunoreactivity was not seen in hyperplastic/non-neoplastic hepatocellular 
lesions such as focal nodular hyperplasia (Table 1, case 18). 
 
DISCUSSION 
Recent studies, both in Drosophila and mammals, have implicated the Hippo signaling 
pathway as a potent regulator of organ size and tissue homeostasis. Indeed, studies from 
different groups employing genetically modified animals showed that the overexpression of 
YAP and the combined Mst1/2 deficiency lead to massive liver overgrowth and 
development of HCC [7-8]. Notably, Mst1/2 or Sav ablation in mouse liver originated mixed 
HCC and cholangiocarcinomas and resulted also in oval cell accumulation [9,11]. Later on, 
more strength to the critical role of dysregulation of the Hippo pathway in liver cancer 
development has come from the finding of its widespread involvement in human cancer 
[13], including HCC and CC, suggesting that this pathway might be an attractive 
therapeutic target.   
Our study demonstrates that the expression of YAP is increased in very early 
preneoplastic hepatocyte foci in two non-transgenic models of hepatocarcinogenesis. 
These results strongly support the notion that the inactivation of the Hippo pathway allows 
genetically damaged cells to evade the intrinsic size-control mechanisms that normally 
  
12 
 
maintain tissue homeostasis, thus favouring their progression to malignancy. Moreover, 
we also present data confirming the involvement of YAP in liver overgrowth in non-
genetically modified animals. As shown, in fact, hepatomegaly induced by activation of the 
nuclear hormone receptor CAR was associated with accumulation of YAP, and VP-
mediated YAP inhibition resulted in severe reduction of liver overgrowth and cell 
proliferation.  
Notably, the increased accumulation of YAP in preneoplastic lesions was associated to a 
concomitant down-regulation of the β-TRCP E3 ligase - which mediates YAP degradation - 
and of miR-375- known to target YAP. MiRNAs have recently emerged as important 
modulators of gene expression in cancer, including human HCC [32]. Down-regulation of 
miR-375 has been observed in human and mouse HCC [26,27] Although the inverse 
relationship between miR-375 and YAP found in the present study is only correlative, 
based on previous works showing that miR-375 does indeed target YAP and impairs HCC 
cell growth, the early dysregulation of this miR herein reported suggests its critical role not 
only for HCC progression, but also for the onset of this tumor.  
Unexpectedly, immunohistochemistry showed YAP accumulation in the cytoplasm but not 
in the nuclei of the actively proliferating preneoplastic and dysplastic hepatocytes. Indeed, 
its phosphorylation in Serine 127 and subsequent cytoplasmic accumulation should reflect 
the activation of the Hippo pathway and the inability of YAP to translocate into the nucleus 
and activate transcription of its target genes. However, the expression of many YAP target 
genes was strongly induced in early preneoplastic hepatocytes, indicating the active co-
transcriptional activity of YAP. The observation that VP, a disruptor of TEAD-YAP binding, 
was able to inhibit the in vivo expansion of initiated cells demonstrates that, in spite of its 
main cytoplasmic accumulation, YAP is transcriptionally active in preneoplastic 
hepatocytes.   
Another interesting observation was that, in the R-H model, YAP accumulates in the 
cytoplasm of facultative adult liver stem cells, known as oval cells, as well; these cells, 
together with preneoplastic hepatocytes, are indeed capable to proliferate after PH in the 
presence of the mitoinhibitory effect exerted by 2-AAF. Even if previous work in transgenic 
animals has shown that the mammalian Hippo pathway is required to repress the 
activation of oval cells [15, 9,11], whether YAP is critical for the survival/expansion of this 
cell subset in non-transgenic models remains elusive. Our finding that i) VP completely 
inhibits the expansion of oval cells in vivo, ii) VP inhibits proliferation of the mouse MLP29 
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oval cells in vitro, and, iii) transduction of MLP29 cells with wild type or active YAP confers 
tumorigenic capacity in vivo, demonstrates that YAP is critical for the expansion of this cell 
population and its progression to cancer.  
Our results also show that low- and high-grade dysplastic nodules, considered as the 
earliest stages analyzable in humans, and which display strict similarities to the 10-week 
nodules seen in the rat model [24], exhibit YAP in the cytoplasm, although at quite low 
levels. Moreover, a novel and interesting finding was the massive YAP accumulation in 
adenomas, arising in an otherwise healthy liver where YAP overexpression was found to 
occur independently from β-catenin mutations or the histological type. The latter findings 
are in disagreement with a previous work (33) revealing weak/absent staining for YAP in 
hepatocellular adenomas; however, they are in accordance with the work of Anakk et al 
(34) who also found YAP staining in adenomas. The reason for these discrepancies are 
not obvious and require further investigation. Why YAP is expressed at such high levels in 
human adenomas is unclear. However, since these tumors arise in a quiescent liver, it can 
be hypothesized that dysregulation of the Hippo pathway is a key event through which 
initiated/mutated cells can escape the growth suppressive signals controlling the size of 
the organ, thus clonally expanding to develop a tumoral mass.   
In conclusion, our present data demonstrate that YAP overexpression and Hippo pathway 
dysregulation are early events in rat and human hepatocarcinogenesis, Moreover, the 
finding that impairment of TEAD-YAP binding inhibits the growth of preneoplastic 
hepatocytes and abolishes proliferation of oval cells suggests a causal relationship 
between YAP activation and liver tumor development, independently of their origin. All 
together, these results provide further evidence to the notion that pathways governing 
tissue overgrowth should be deeply explored as potential therapeutic targets in human 
HCC.  
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LEGEND TO FIGURES  
 
Figure 1. YAP accumulates in early preneoplastic lesions and oval cells. F-344 rats 
submitted to the R-H protocol were sacrificed 7 days after PH (foci) or at 10 weeks 
(nodules) or 14 months (HCCs) from DENA treatment. (A) GSTP, YAP and phosphoYAP 
(pYAP) immunohistochemistry of serial sections through preneoplastic foci (x4). The 
analysis of the total number of YAP positive foci was performed on liver sections from 6 
animals. An average of about 50 YAP-positive foci/liver section was counted for each liver 
slide. Similar results were obtained in 3 independent experimental protocols (B) YAP and 
pYAP positivity pattern in oval cells (x4). (C) GSTP, YAP and pYAP immunohistochemistry 
of serial sections of 10-week dysplastic nodules (x4). (D) nuclear YAP positivity in rat 
HCC, and intense YAP staining in lung metastases (x10). (E) YAP mRNA levels in early 
preneoplastic foci and HCC, NS: not statistically significant. (F) qRT-PCR analysis of 
β−TRCP expression in early preneoplastic foci, ***statistically significant for P<0.001 (G,H) 
qRT-PCR analysis of microRNA-375 expression in dysplastic nodules and HCCs. In all the 
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panels values are compared to controls (animal livers of the corresponding age) 
considered as 1, and expressed as mean ±.SEM. Statistically significant for **P<0.01.  
Figure 2. Verteporfin (VP) administration reduces  number and size of preneoplastic 
GSTP-positive foci, and impairs viability of HuH7 and MLP29 cells. Rats exposed to 
the R-H protocol were injected intraperitoneally with VP (100 mg/kg) 1 hour prior to- and 3 
and 5 days after PH. Animals were sacrificed 7 days after PH. (A) GSTP 
immunohistochemistry of liver sections from rats with (+VP) or without (-VP) VP treatment 
(x4). (B) Effect of VP administration on the number of GSTP-positive foci, the mean 
GSTP-positive area and the percentage of the area occupied by GSTP-positive 
hepatocytes. Values are expressed as mean ±.SEM. Statistically significant for *P<0.05, 
**P<0.01 (C) KRT-19 immunohistochemistry staining illustrating a remarkable inhibition of 
oval cell proliferation in VP-treated rats; (x4 up) and (x20 down). (D) Effect of different 
doses of VP on viability of Huh7 cells. Huh7 transduced with empty vector (Huh7 pRRL2) 
or with YAP wt (Huh7 YAP WT) were treated with the indicated VP concentrations. 
Viability was evaluated 6 days after seeding. SD is indicated. Statistically significant for 
*P<0.05; **P<0.01;***P<0.001; E) Effect of VP on viability of MLP29 cells treated or nor 
with VP, in the absence or in the presence of 40 ng/ml of HGF. Viability was evaluated 3 
days after seeding; SD is indicated. Statistically significant for *P< 0.05. 
Figure 3. Effect of transduction of MLP29 cells with WT or active YAP on colony 
forming ability and tumorigenic properties. (A) MLP29 cells infected with (i) empty 
vector (MLP pRRL2), (ii) YAP wt (MLP YAP WT) or (iii) active YAP (MLP YAP SS), were 
grown in agar for 3 weeks. The number of viable cells was quantified with the Alamar Blue 
dye. Representative pictures are shown. SD is indicated. Statistically significant 
for*P<0.05; **P<0.01. (B) Mice were subcutaneously injected with MLP pRRL2, MLP YAP 
WT or MLP YAP SS. Mean tumor volume +SD was evaluated at the indicated times; 
statistically significant for *P<0.05; **P<0.01. (C) H&E staining of lung sections of mice 
subcutaneously injected with MLP pRRL2, MLP YAP WT or MLP YAP SS (x4). (D) (left 
graph) Percentage of the lung area covered by metastases calculated using the ImageJ 
software; (right graph) number of metastatic lesions/mice. These values have been 
calculated in 5 different slides for each mouse. Values are expressed as mean ±.SEM.. 
Statistically significant for *P<0.05; ***P<0.001;  
Figure 4: YAP immunoreactivity in dysplastic nodules and in different subtypes of 
hepatocellular adenomas. (A,B) Low grade dysplastic nodule: (A) H&E staining; x10; (B) 
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YAP staining showing some immunoreactive cells with cytoplasmic staining 
immunoreactivity (x40); (C) High grade dysplastic nodule: YAP staining showing an 
increased number of YAP immunoreactive cells with granular cytoplasmic staining (x20) 
(D-F) Atypical and β-catenin mutated adenoma: (D) H&E staining, (x10); (E) β-catenin 
staining showing nuclear localization (x10) and (F) YAP staining showing diffuse 
cytoplasmic granular positivity (x20); (G-I) steatotic adenoma and surrounding 
parenchyma: (G) H&E staining, (X4); (H) YAP staining showing that YAP expression is 
restricted to the adenomatous component (x4); (I) higher magnification showing 
cytoplasmic and nuclear YAP immunostaining of the adenoma (x20); (L-N) telangiectatic 
adenoma: (L-M) H&E staining (x10 and x20); (N) YAP staining showing moderate, 
granular cytoplasmic YAP staining in the majority of tumor cells (x20). 
 
  
  
  
  
  
Table 1: YAP immunoreactivity in human dysplastic nodules and hepatocellular adenomas 
Lesion Clinical features Histopathological diagnosis YAP immunoreactivity 
1 
Male; 60 yrs; HCV related cirrhosis; 
0.9 cm size 
 
LGDN 
 
10%,+, C 
2 
Male; 61 yrs; alcohol related cirrhosis; 
1 cm size 
 
LGDN 
 
Negative 
3 Male; 57 yrs; HCV and alcohol related 
cirrhosis; 
3.0 cm size 
LGDN 10%,+, C 
4 Male; 64 yrs; HBV and alcohol related 
cirrhosis;  
1.7 cm size 
HGDN 10%, ++,C 
5 Male; 67 yrs; HCV related cirrhosis;  
1 cm size 
HGDN Negative 
6 Male 74 yrs; metabolic cirrhosis,  
1.2 cm size 
HGDN 10%, ++, C 
7 Female 33 yrs; HBV and HCV negative; 
multiple  (> 10) liver lesions 
Hepatocellular adenomatosis 
steatotic subtype 
30%, ++, C 
8   40%, ++, C 
9   40%, ++, C  
10   70%, ++, C 
11   70%, +++, C (isolated N) 
12 Female 38 yrs; HBV and HCV negative, 
Oral contraceptive assumption; 
Multiple (> 10) liver lesions 
Hepatocellular adenomatosis 
steatotic subtype 
     
                80%,+++,C 
 
13 Female 51 yrs; HBV and HCV-negative 
dyslipidemic syndrome; 
multiple (>10) liver lesions 
Hepatocellular adenomatosis 
steatotic subtype 
     40%, +++,C 
14 Male, 53 yrs, 
 8 cm size 
Hepatocellular adenoma 
telangiectatic subtype 
70%,+++,C (isolated N) 
15 Female, 40 yrs,  
7 cm size 
Hepatocellular adenoma 
telangiectatic subtype 
      10%, ++, C (isolated N) 
16 Male, 19 yrs;  
12 cm size 
 
HCC (G1) arising within a        
hepatocellular adenoma,            
telangiectatic and with         
-catenin activation 
 
70%, +++, C 
17 Male, 26 yrs,  
10 cm size 
HCC (G1) arising within an         
atypical hepatocellular adenoma, 
with -catenin activation 
 
80%, +++, C 
18 Female, 23 yrs, HBV and HCV negative 
(2 liver lesions) 
5 and 1.5 cm size 
 
Multiple focal Nodular 
Hyperplasia 
Negative 
 
LGDN: Low grade dysplastic nodules; HGDN: High grade dysplastic nodules  
The number of YAP-positive cells is expressed as percentage (%);  
C: cytoplasmic localization; N: nuclear localization. 
The staining intensity is expressed as + (faint); ++ (moderate); +++ (strong) 
